Amati L, Caradonna L, Magrone T, Mastronardi M L, Cuppone R, Cozzolongo R, Manghisi O G, Caccavo D, Amoroso A, Jirillo E
Laboratories of Immunopathology, Scientific Institute for Digestive Diseases, Castellana Grotte, Bari, Italy.
Curr Pharm Des. 2002;8(11):981-93. doi: 10.2174/1381612024607036.
The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-gamma)] have been demonstrated to mediate the antiviral immune response. Serum levels of Th1 cytokines (IL-2 and IFN-gamma) as well as of Th2 products (IL-4 and IL-10) were determined in a group of HCV-positive patients before and after treatment with IFN-alpha and Ribavirin (RIB). Results indicate that responder patients exhibited increased levels of IFN-gamma and IL-10, while this enhancement was not observed in non-responder patients. In this respect, the major effect exerted by the combined therapy with IFN-alpha/RIB could be represented by the attainment of a re-equilibrium between inflammatory (Th1) and antiinflammatory (Th2) mechanisms. In this framework, according to current literature, novel therapeutical approaches to treat HCV infection are represented by administration of recombinant IL-2 and IL-10.
辅助性T细胞（Th）1和Th2反应之间的平衡似乎是丙型肝炎病毒（HCV）感染发展过程中的一个关键事件。特别是，Th1细胞因子[白细胞介素（IL-2）和干扰素（IFN-γ）]已被证明可介导抗病毒免疫反应。在一组HCV阳性患者接受α干扰素和利巴韦林（RIB）治疗之前和之后，测定了Th1细胞因子（IL-2和IFN-γ）以及Th2产物（IL-4和IL-10）的血清水平。结果表明，有反应的患者IFN-γ和IL-10水平升高，而无反应的患者未观察到这种增强。在这方面，α干扰素/RIB联合治疗的主要作用可能表现为炎症（Th1）和抗炎（Th2）机制之间重新达到平衡。在此框架下，根据当前文献，治疗HCV感染的新治疗方法是给予重组IL-2和IL-10。
